CMA: Immune/inflammatory priming in exacerbating responses to GWVI stressors: implications for GWVI treatments

CMA:免疫/炎症引发加剧对 GWVI 应激源的反应:对 GWVI 治疗的影响

基本信息

项目摘要

Project Summary/Abstract This Collaborative Merit Review Award for Research (I01) proposed in response to RFA BX-18-007 from the Veteran Health Administration is a joint effort by investigators from the JJ Peters VA Medical Center (Bronx, NY) Project 1, Arnold School of Public Health and Wm Jennings Bryan Dorn VA Medical Center (Columbia, SC) Project 2, Brain Science Center VA Medical Center (Minneapolis, MN) Project 3. We define a vision for an integrated and multidisciplinary program of preclinical research projects all linked by the ultimate goal to better characterize the mechanism of persistent and aberrant immunological activity in Gulf War Veteran Illnesses (GWVI) by developing experimental model systems, with the ultimate goal of developing novel therapeutic interventions. Gulf War Veterans’ Illnesses is a multifaceted disorder characterized by a range of symptoms including cognitive impairment, fatigue, pain, mood disorders, among others. Recent evidence suggests that the onset and progression of these symptoms may be the result of disequilibrium in these subjects’ immune systems. During deployment GWV were exposed to a unique variety of toxic agents that were specific to the Gulf War theatre, such as pyridostigmine bromine (PB), diisopropyl fluorophosphates (DFP), permethrin, and depleted uranium which current evidence indicates lowered thresholds to immunological responses and resulted in the persistent and heightened activity of certain arms of the immune system; a phenomenon best described as “immunological priming”. In addition, they received more than 20 vaccines that could have overloaded the immune system. In support of these considerations, subjects with GWVI often have shown pathological signatures in common with autoimmune disorders and generalized inflammatory disorders, such as increased plasma concentrations of pro-inflammatory cytokines, unspecific tissue degeneration, and organ failure. Based on this concept, the three proposed collaborative research projects were designed to better understand how primed immune systems may contribute to GWVI- type phenotypes by exploring how multiple GWI conditions recapitulated in animal models may synergize and eventually provide new mechanistic evidence for translation studies. For example, Project 2 was designed to understand how GW toxin induced gut inflammasome activation causes gut dysbiosis and may lead to persistent or heightened immune-inflammatory responses and GWVI symptoms. As the goal of Project 3 is designed the hypothesis that lack of specific immunity leads to vaccine-induced inflammatory reaction in the brain, Project 2 will collaborate with project 3 to test the contribution of inflammasome priming and genetic diversity to gut dysbiosis and persistent immunological responses. Similarly, Project 1, which is designed to test how immunological priming may heighten inflammatory responses to psychological stressors, will collaborate with project 2 and project 3 by exploring how the NLRP3 inflammasome may contribute to heightened inflammation induced by gut dysbiosis or HLA polymorphisms, respectively. The outcome of these studies is of great interest not only because this will establish a novel link between inflammasome priming, genetic diversity and gut-dysbiosis toxemic response, but it will also provide insight to test novel therapeutic approaches that target the persistent activation of the immune system, either using immunotherapeutic approaches against vaccine toxins, probiotics to attenuate gut dysbiosis. Our proposed studies are innovative in terms of their scope, since it will fill the fundamental gaps needed for future translational studies. Most importantly our multiscale technological innovative approaches, which include knockout murine models of GWVI, including for the HLA and NLRP3 proteins, will enable our interdisciplinary research team with outstanding expertise in neuroscience, pharmacology, microbiology, chemistry to thoroughly investigate the molecular mechanisms underlying the etiology of GWVI.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Giulio Maria Pasinetti其他文献

Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease
  • DOI:
    10.1016/0169-328x(95)00097-c
  • 发表时间:
    1995-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Philippe Bertrand;Judes Poirier;Tomiichiro Oda;Caleb E. Finch;Giulio Maria Pasinetti
  • 通讯作者:
    Giulio Maria Pasinetti
Differential susceptibility to repeated social stress induces synaptic plasticity impairment and cognitive deficit in the 5xFAD mouse model
对重复社会应激的差异易感性在 5xFAD 小鼠模型中诱导突触可塑性损伤和认知缺陷
  • DOI:
    10.1016/j.pneurobio.2025.102797
  • 发表时间:
    2025-08-01
  • 期刊:
  • 影响因子:
    6.100
  • 作者:
    Eun-Jeong Yang;Md Al Rahim;Sibilla Masieri;Giulio Maria Pasinetti
  • 通讯作者:
    Giulio Maria Pasinetti
The Role of the Neural Exposome as a Novel Strategy to Identify and Mitigate Health Inequities in Alzheimer’s Disease and Related Dementias
  • DOI:
    10.1007/s12035-024-04339-6
  • 发表时间:
    2024-07-05
  • 期刊:
  • 影响因子:
    4.300
  • 作者:
    Ravid Granov;Skyler Vedad;Shu-Han Wang;Andrea Durham;Divyash Shah;Giulio Maria Pasinetti
  • 通讯作者:
    Giulio Maria Pasinetti
61 Repurposing anti-hypertensive drugs for Alzheimer's disease
  • DOI:
    10.1016/j.neurobiolaging.2012.01.079
  • 发表时间:
    2012-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Giulio Maria Pasinetti;P. Rosenberg
  • 通讯作者:
    P. Rosenberg
P27-030-23 Flavonoids Ameliorate Stress-Induced Depression by Preventing NLRP3 Inflammasome Priming
  • DOI:
    10.1016/j.cdnut.2023.101237
  • 发表时间:
    2023-07-01
  • 期刊:
  • 影响因子:
  • 作者:
    Giulio Maria Pasinetti;Eun-Jeong Yang
  • 通讯作者:
    Eun-Jeong Yang

Giulio Maria Pasinetti的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Giulio Maria Pasinetti', 18)}}的其他基金

Validation of Immune Dysfunction in Model of Social Stress: Implications for Major Depression Disorder in Veterans
社会压力模型中免疫功能障碍的验证:对退伍军人重度抑郁症的影响
  • 批准号:
    10293590
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Validation of Immune Dysfunction in Model of Social Stress: Implications for Major Depression Disorder in Veterans
社会压力模型中免疫功能障碍的验证:对退伍军人重度抑郁症的影响
  • 批准号:
    10618776
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Validation of Immune Dysfunction in Model of Social Stress: Implications for Major Depression Disorder in Veterans
社会压力模型中免疫功能障碍的验证:对退伍军人重度抑郁症的影响
  • 批准号:
    10016566
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Administrative, Biostatistics, and Management Core
行政、生物统计和管理核心
  • 批准号:
    10200690
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Suppression of Immune Signatures of Stress by Polyphenols Supplements
多酚补充剂抑制压力的免疫特征
  • 批准号:
    10447073
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Suppression of Immune Signatures of Stress by Polyphenols Supplements
多酚补充剂抑制压力的免疫特征
  • 批准号:
    10671048
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Administrative, Biostatistics, and Management Core
行政、生物统计和管理核心
  • 批准号:
    10447076
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Suppression of Immune Signatures of Stress by Polyphenols Supplements
多酚补充剂抑制压力的免疫特征
  • 批准号:
    10200686
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Administrative, Biostatistics, and Management Core
行政、生物统计和管理核心
  • 批准号:
    10671063
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
CMA: Immune/inflammatory priming in exacerbating responses to GWVI stressors: implications for GWVI treatments
CMA:免疫/炎症引发加剧对 GWVI 应激源的反应:对 GWVI 治疗的影响
  • 批准号:
    10266035
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了